טוען...
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
BACKGROUND AND AIMS: Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn’s disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there a...
שמור ב:
| הוצא לאור ב: | Dig Dis Sci |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369127/ https://ncbi.nlm.nih.gov/pubmed/31970610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-06036-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|